Latest Bacillus Calmette-Guérin Stories

2009-05-21 21:24:06

U.S. scientists say the tuberculosis vaccine has not weakened but changed and could be made effective again. Their findings, published in PLoS ONE, could help make the TB vaccine effective again in preventing the bacterial lung infection. Our findings represent nearly a 180-degree reversal from the dogma of the last 60 years -- that the TB vaccine stopped working because it became over-attenuated and was too 'wimpy' to be effective, Dr. Douglas Kernodle of Vanderbilt University Medical...

2009-05-20 07:10:04

Modifications could improve TB vaccine, offer platform for other vaccines A team of Vanderbilt University Medical Center investigators has cracked one of clinical medicine's enduring mysteries "“ what happened to the tuberculosis vaccine. The once-effective vaccine no longer prevents the bacterial lung infection that kills more than 1.7 million people worldwide each year. Their solution, reported in the journal PLoS ONE, could lead to an improved TB vaccine and also may offer a novel...

2009-04-16 09:49:22

A study by researchers from the University of California, San Diego School of Medicine, in collaboration with Mexican researchers and health officials, shows that as many as 67 percent of injection drug users in Tijuana test positive for tuberculosis (TB) infection. The analysis, which underscores the urgent need for TB screening and treatment for populations that are also at risk for HIV infection, will be published in the May issue of the International Journal of Tuberculosis and Lung...

2009-04-02 08:45:05

A once widely-used vaccine against tuberculosis, bacillus Calmette-Gu©rin, or BCG, provides only partial protection against the ancient disease that kills more than 1 million people each year.Now researchers at Baylor College of Medicine and The University of Texas Medical School at Houston hope that they can harness an immune function called autophagy to make the vaccine more effective for longer periods of time. A report on their work appears in a recent issue of the journal Nature...

2009-04-01 13:44:57

U.S. researchers say they've identified, for the first time, an enzyme that is essential to the onset of depressive symptoms caused by chronic inflammation. The University of Illinois scientists identified the enzyme IDO (indoleamine 2,3 dioxygenase) as a molecular switch that induces depressive symptoms in some cases. Physicians have long known patients with chronic inflammation, such as coronary heart disease or rheumatoid arthritis, are more likely than others to become depressed, the...

2009-03-31 06:00:00

-105 high-grade refractory patients recruited in trial; complete efficacy data to be available in one year- BELLEVILLE, ON, March 31 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has completed recruitment in its initial Phase III registration trial evaluating Urocidin(TM) in the treatment of non-muscle-invasive bladder cancer that is refractory...

2009-03-04 09:05:22

A breakthrough strategy to improve the effectiveness of the only tuberculosis vaccine approved for humans provided superior protection against the deadly disease in a pre-clinical test, report scientists at The University of Texas Health Science Center at Houston in Nature Medicine's Advance Online Publication March 1. Their findings resulted from more than 6 years of research funded by the National Institutes of Health (NIH). Bacille Calmette-Gu©rin (BCG) provides only partial...

2009-02-18 06:00:00

- results from this trial supported entry into Company's current Phase III bladder cancer program - BELLEVILLE, ON, Feb. 18 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that The Journal of Urology has published an article summarizing the Phase II clinical trial results for the Company's proprietary Mycobacterial Cell Wall technology in bladder cancer. The article, entitled...

2008-11-13 06:00:36

Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue. Vaccine Technologies and Global Markets http://www.reportlinker.com/p096550/Vaccine-Technologies-and- Global-Markets.html (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) Through the late 1980s, the vaccine market was beset by limited portfolios...

2008-10-25 12:13:31

UCLA scientists engineered a new tuberculosis (TB) vaccine specifically designed for HIV-positive people that was shown to be safer and more potent than the current TB vaccine in preclinical trials. A more effective TB vaccine may help curtail the global spread of the disease, especially in HIV-positive people, for whom tuberculosis is the leading cause of death worldwide. "The AIDS and tuberculosis epidemics are now so intertwined in many parts of the world that we can't win the fight...

Latest Bacillus Calmette-Guérin Reference Libraries

2011-04-18 22:11:24

Mycobacterium bovis is a slow-growing, aerobic bacterium and the causative agent of tuberculosis in cattle. Similar to M. tuberculosis, M. bovis can jump the species barrier and cause tuberculosis in humans. It is estimated that M. bovis was responsible for more losses among farm animals than all other diseases combined in the first half of the 20th century. Infection happens after bacterium is ingested. It is generally transmitted to humans via infected milk. Actual human infections are...

More Articles (1 articles) »
Word of the Day
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'